Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.
- Eligible Ages
- Between 18 Years and 80 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Adults (18-80 years old)
- within 48 hours of their hospitalization for infection with SARS-CoV-2
- PCR positive for SARS-CoV-2 within 48 hours of study entry
- Subject or their legal representative understands the requirements of the study and provides written informed consent prior to undergoing any treatment-related procedures.
- Subject has a concomitant bacterial respiratory infection unless cleared by the Sponsor
- Subject has a history of abnormalities of uric acid metabolism unless cleared by the Sponsor.
- Subject has a history of hypersensitivity to an anti-viral nucleoside analog drug targeting a viral RNA polymerase
- Subject is using adrenocorticosteroids (except topical or inhaled preparations or oral preparations equivalent to or less than 10 mg of oral prednisone) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers).
- Subject has a serious chronic disease (e.g., human immunodeficiency virus (HIV), cancer requiring chemotherapy within the preceding 6 months, moderate or severe hepatic insufficiency and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days).
- Has previously received favipiravir within the past 30 days
- Has renal insufficiency requiring hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) or glomerular filtration rate of less than 20 mL/min.
- Has liver impairment greater than Child-Pugh A.
- Has a history of alcohol or drug abuse in the previous 6 months.
- Has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year.
- Has taken another investigational drug within the past 30 days.
- Is on another antiviral or is participating in another clinical trial for the treatment of COVID-19
- Subject is on a ventilator at the time of study entry
- Is deemed by the Investigator to be ineligible for any reason.
- Phase 2
- Study Type
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Open-label, randomized (1:1 ratio) to receive favipiravir plus standard of care or standard of care alone.
- Primary Purpose
- None (Open Label)
Favipiravir Treatment Arm
|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC||
Standard of Care Arm
|Standard of Care for 14 days||
- Fujifilm Pharmaceuticals U.S.A., Inc.
Study ContactFPHU Study Coordinator
This is an open label, randomized, controlled, multicenter Phase 2 proof-of-concept study of favipiravir in hospitalized subjects with COVID-19. Subjects will be randomized within their study site and stratified by the severity of their disease to receive either favipiravir + standard of care (SOC) or SOC alone.
The dose regimen will be 1800 mg favipiravir BID plus SOC or SOC alone on Day 1 followed by 1000 mg BID favipiravir (800 mg BID for subjects with Child-Pugh A liver impairment) plus SOC or SOC for the next 13 days.
The study will have 14 days of treatment and 46 days of follow-up.
Approximately 50 patients are planned to be enrolled in the trial at 3 study sites in the US.